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Abstract 
For patients with incurable neurodegenerative disorders such as Huntington’s (HD) and Parkinson’s 
disease, cell transplantation has been explored as a potential treatment option. Here we present the 
first clinico-pathological study of a patient with HD in receipt of cell-suspension striatal allografts who 
took part in the NEST-UK multi-centre clinical transplantation trial. Using various immunohistochemical 
techniques, we found a discrepancy in the survival of grafted projection neurons with respect to grafted 
interneurons as well as a major ongoing inflammatory and immune responses to the grafted tissue with 
evidence of mutant huntingtin aggregates within the transplant area. Our results indicate that grafts can 
survive more than a decade post-transplantation but show compromised survival with inflammation and 
mutant protein being seen within the transplant site.  
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Introduction 
Huntington’s Disease (HD) is an autosomal dominant neurodegenerative disorder that presents with a 
combination of motor, cognitive and psychiatric problems that progress over a 20-year period to death. 
It is currently incurable and while many therapies have been the subject of clinical trials, none have 
been shown to alter the natural history of this condition 1. More than twenty years ago, work 
commenced on a novel strategy that involved allografting foetal tissue into the striatum of patients with 
mid-stage disease to attempt to repair the damaged circuitry, as had been shown preclinically using 
excitotoxic lesions of the rat and monkey striatum 2. To date, seven small open-label studies of neural 
transplants have been conducted worldwide assessing the feasibility, safety, and tolerability of this 
procedure in patients with HD 3-9. This approach has yielded mixed results including post-mortem 
analysis of transplanted patients. Here we present long-term histological data on 1 of the 5 patients 
treated with a fetal striatal cell suspension allograft as part of the UK study 4.  
 
Methods 
Trial information  
This patient was one of 5 who were part of the NEST-UK multicentre study which was initiated in 1998 
to evaluate the safety and efficacy of bilateral fetal striatal transplantation in patients with mild HD 
(ISRCTN no 36485475) 4. The operations were undertaken in Cambridge between 2000 and 2003 and 
this report deals with patient number 5, the only one to receive bilateral transplants of fetal striatal 
tissue in a single operation. The trial was approved by the Cambridge Regional Ethics Committee (REC 
ref: 95/086), as was the post-mortem analysis (REC ref:01/117). 
 
Tissue preparation and neurosurgical procedures 
Details of tissue procurement and preparation, immunosuppression, safety assessment and 
implantation have been fully reported elsewhere 4, 10-12. The patient was followed up using the standard 
CAPIT-HD protocol 4,5. 
 
Post-mortem histological evaluation  
The brain was removed 37.3 hours after death and processed as described in 13. Sections were initially 
processed for histochemical analyses to assess graft location, survival and cyto-architecture. For this, 1 
section of each graft was stained for acetylcholinesterase (AChE), as described in 16. 
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Immunohistochemistry 
For immunohistochemical stainings, the following primary antibodies were used: the neuronal marker 
MAP2 (rabbit anti-MAP2, Proteintech, 17490-1-AP, 1:500) or NeuN (mouse anti-NeuN, Millipore, 
MAB377, 1:2500) with the mutant huntingtin (mHtt) antibody (EM48, Millipore, MAB5374, 1:500). For 
striatal projection neurons, we used the calcium-binding protein calbindin (rabbit anti-CB, Abcam, 
Ab11426, 1:1000) and the Dopamine- and cAMP regulated neuronal phosphoprotein DARPP-32 (rabbit 
anti-DARPP-32, Cell Signaling, 2306, 1:1000). To identify grafted interneurons, we used calretinin (rabbit 
anti-CR, Swant 7699/4, 1:1000), parvalbumin (mouse anti-PV, Sigma, P3088, 1:1000) and choline 
acetyltransferase (Ms-anti-ChAT, Millipore MAB5270, 1:200), as previously described 14. We also 
performed an histochemical staining for nicotinamide adenine dinucleotide phosphate (NADPH-d) - a 
marker for nitric oxide containing striatal interneurons - following previously published protocols 14, 15. 
The inflammatory/immune response was visualised using the microglial marker Iba1 (rabbit anti-Iba1, 
Wako, LAK4357, 1:500), the T helper cell marker CD4 (mouse anti-CD4, Leica, NCL-L-CD4-368, 1:500) and 
the natural killer and cytotoxic T cells CD8 (mouse anti-CD8, Leica, NCL-L-CD8-4B11, 1:500). Sections 
stained for immune cells (CD4 and CD8) were further pre-treated in a 10mM sodium citrate buffer 
solution at 80ᵒC for 20 minutes. In some cases, immune cells were also counterstained with Nissl. 
Finally, a single immunohistochemistry staining for tyrosine hydroxylase (TH) (rabbit anti-TH, Pel Freeze 
Biologicals, P40101-150, 1:1000) was used to assess the dopaminergic innervation of the graft. In all 
cases, sections were incubated with appropriate secondary antibodies (Biotinylated Goat anti-mouse 
IgG, Vector, BA9200 1:500, Biotinylated Goat anti-rabbit IgG, Vector, BA1000 1:500) using the ABC Elite 
Vectastain® Kit (Vector Laboratories).  
 
Image acquisition and quantification  
Brightfield photomicrographs were taken using the Picture Frame software (Microbrightfield) attached 
to an E800 Nikon microscope (Nikon Instruments) and prepared for illustration using Adobe Photoshop 
CS5 and final figure panels assembled using Adobe Illustrator CS5. 
 
All cell quantifications were performed on two sections of the cortex and striatum containing the graft. 
The perimeters of the grafted areas were delineated using the tracing contour option in Stereo 
Investigator (NeuroExplorer, version 10.0; Microbrightfield) as described in 16. To measure the 
cholinergic activity, images of the AChE stainings were processed with ImageJ software and P-zones, non 
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P-zones, and the host striatum were individually traced. These areas were measured for their mean gray 
values of color intensity. 
 
Statistical analysis  
For all cell quantifications, an unpaired Student’s t-test was performed using Prism (6.0; Graph-Pad 
Software Inc., La Jolla, CA).  
 
Results 
Clinical course 
The patient first noticed problems in 1995, at the age of 37, with a slight change in his mood and his 
family became aware of his problems in 1997 when he developed nightmares and depression. He had a 
family history for HD and went on to have a positive genetic test with an expansion of 47 CAG repeats in 
exon 1 of the huntingtin gene. In 2003, he was selected for neural grafting and underwent a bilateral 
transplant procedure without complications and was followed up according to the CAPIT-HD protocol 
until his death in 2015. His clinical history showed no obvious change in his disease course after grafting, 
either clinically or on PET imaging, as detailed in 4. 
 
Post-mortem graft evaluation  
Graft location and cytoarchitecture  
Macroscopically grafts were easily identified. In total, six grafts were located in the left hemisphere with 
2 in the caudate, and 4 in the putamen (Figure 1A-B’) while on the right only 1 and 2 grafts in these 
structures were found respectively (Figure 1C-E).  
 
General graft health  
All the typical phenotypes of striatal interneurons were observed within the grafted tissue including cells 
positive for CR, PV, NADPH and ChAT (Figure 1F-I). They showed healthy morphologies and extensive 
dendritic arborizations. Stereological quantifications for each of these cell types revealed similar counts 
within the transplanted area in comparison to the host striatum for CR, PV, and NADPH interneurons 
(Figure 1F’, G’, H’ and I’). Despite rare examples of healthy MAP2 staining within the graft (Figure 1J), 
the presence of DARPP-32-positive cells was almost exclusively seen within the host striatum (Figure 
1K). Grafted projections neurons, as also identified with CB, were largely necrotic (Figure 1L,L’) and 
there were fewer cells within the transplant area. Due to the tested antibody being discontinued, we 
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used the AChE staining to measure the cholinergic enzyme levels within the P-zones and compared them 
to the host striatum, and they looked similar (Figure 1I’). 
 
The inflammatory-immune response to cell suspension grafts  
A ring of densely packed, maximally hyperactive microglia surrounded each of the transplanted sites 
(Figure 2A, B), and was also present within the graft itself. Throughout this ring, the spectrum of 
microglial activation was represented from dystrophic (Figure 2C, D), clustered (Figure 2E) and rod 
(Figure 2H) cells. Grafted regions lacking striatal markers (non P-zones), had qualitatively much lower 
microglial density, though the microglial morphology and Iba1 intensity remained consistent with a pro-
inflammatory phenotype (Figure 2F, G). As senescence continues, these processes become fragmented 
and severe dystrophy was confirmed by spherical microglial cell bodies with no processes, surrounded 
by small dots of cytoplasm apparently disconnected from the soma (Figure 2I). The outer borders of the 
graft contained more dystrophic microglia, with gnarled, beaded processes (Figure 2 J, K). The host 
tissue, on the other hand, was almost entirely populated by dystrophic and non-functional microglia. 
The p-zones contained the highest ratio of ramified microglia and the fewest dystrophic cells (Figure 2L), 
although there were still many more hyperactive cells than normally present in healthy tissue. 
 
Graft innervation and presence of HD-related pathology 
The grafts received modest innervation, as evidenced by the sparse dopaminergic fibres seen near the 
transplants (Figure 3A, B). Several mHtt+ aggregates were seen within the graft site and at the 
graft/host interface (Figure 3C, D). The mHtt+ aggregates were not only seen within the extracellular 
matrix of the grafted area, as previously reported in solid tissue transplants 16, but they were also found 
within cell bodies in the grafts (Figure 3F, G, H, L). A particularly interesting observation was that some 
mHtt+ aggregates were found along, or even within, the dendritic tree of cells within the transplant 
(Figure 3J, K). Notably, striatal host cells expressing mHtt+ extended their dendritic trees into the grafts 
(Figure 3I, I’).  
 
Finally, groups of T helper cells (stained for cluster of differentiation 4, CD4) (Figure 3M-N) and cytotoxic 
T cells (stained for cluster of differentiation 8, CD8) (Figure 3O-R) were found forming clusters within the 
grafts, indicating an ongoing immune and inflammatory response at the time of death. Of significance, 
the genetic product of HD, mHtt, was also identified within infiltrating T helper cells (Figure 3R). 
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Discussion  
This is the first histological report on striatal cell suspension allografts originating from the UK NEST 
striatal transplantation HD project (NEST-HD) 5, 17. Post-mortem evaluation revealed that (i) it was easy 
to find striatal transplants within which grafted interneurons were largely spared in contrast to the 
grafted projection neurons that were rarely seen; (ii) there was a striking microglial response around the 
graft; iii) there were mHtt aggregates within the grafted tissue as well as within cells of the transplanted 
area and finally, (iv) there was infiltration of immune cells within the grafted tissue that also contained 
mHtt, both of which may have further contributed to poor graft survival. These observations are similar 
to those that we have reported previously in HD patients who receiving solid tissue pieces but 
importantly there were notable differences in that we saw a much more marked infiltration of immune 
cells in the cell suspension grafts along with more florid mHtt cellular pathology within the transplant 
sites.  
 
This latter observation relating to mHtt expression within the grafts requires further comment. One 
could argue that the cells expressing mHtt within the boundaries of the grafted areas are host cells that 
have migrated into the transplant. Alternatively, one could speculate that innervation of the grafts by 
host striatal neurons containing mHtt+ results in the transport of the pathological protein from the host 
to the graft, given that mature striatal cells have little if any migratory capacity 18. Unfortunately, the 
underlying explanation for this finding cannot be explored in this context, as the technical limitations 
inherent to human post-mortem analysis does not allow one to make mechanistic conclusions. 
Additionally, other routes of transport should be considered in light of the fact that mHtt+ was seen, 
although rarely, within CD8+ cells. The significant infiltration of CD4+ and CD8+ cells, notable within the 
grafted areas, may have indeed been facilitated by the more complex and efficient vascularization that 
we saw within the cell suspension grafts (data not shown).  
 
In conclusion, this study again highlights that fetal striatal allografts can survive long-term in the human 
HD brain. However, while interneurons within them survive, projection neurons degenerate, and this is 
all associated with inflammation around and in the transplant as well as the expression of mHtt 
pathology at the graft site. The relevance and mechanistic consequences of these observations awaits 
clarification but raises questions as to whether cell-based approaches for repairing the HD brain can 
ultimately repair the dysfunctional networks seen in this condition 16, 19-26. 
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Figure legends  
Figure 1. Graft location, cytoarchitecture and grafted cell survival. Macroscopic identification of the 
transplants based on AChE staining revealed a total of three grafts in the left hemisphere (delineated by 
dotted lines): one in the upper caudate nucleus (A, A’) and two in the putamen (A, A”, B, B’) that 
occupied between 7.2 and 9.9% of the total striatal area. Cell suspension grafts were observable as 
clusters closely resembling P-zones and NP-zones (A-B’). An additional three grafts were located in the 
right hemisphere (delineated by dotted lines): one in the caudate nucleus (C), and two in the putamen 
(D-E) that were much smaller and occupied less than 1.2% of the total striatal area. 
Immunohistochemical staining for striatal interneurons included CR, PV, NADPH and ChAT (F-I). High 
power photomicrographs highlighting the CR (F) and PV (G) staining of cells within a p-zone of the graft 
as well as examples of grafted neurons expressing NADPH-d (H), or ChAT (I). All grafted interneurons 
showed a rather healthy morphology with extensive dendritic arborizations. Stereological cell counts 
revealed a similar number of CR- (F’), PV- (G’), NADPH- (H’) and ChAT- (I’) immunolabeled cells in the 
grafted area vs. the host striatum. Similar immunohistochemical staining approaches were used to 
identify grafted projection neurons and included MAP2, DARPP-32 and CB (K-L’). While certain p-zones 
displayed a restricted number of healthy MAP2 staining cells (J), DARPP-32+ projection neurons were 
typically absent in the grafted tissue but frequently found within the host striatum (K). In contrast to 
interneurons, detectable CB-immunoreactive projection neurons were largely necrotic (L, L’). 
Stereological cell counts revealed a striking difference between the number of MAP2- (J’), DARPP-32- 
(K’), and CB- (L”) immunolabeled elements in the grafted area vs. the host striatum. Scale bars: A, B, C, 
D, E = 1.25 mm; A’, B’ = 250 µm; A” = 20 µm. F = 100µm; G = 250µm; H, I = 25µm; J = 25µm; K = 50 µm; L 
= 250µm; L’ = 50 µm. Abbreviations: Acetylcholinesterase, AChE; CB; Calbindin; CD, caudate nucleus; 
ChAT, choline acetyltransferase; CR; calretinin; dopamine- and cAMP-regulated neuronal 
phosphoprotein, DARPP-32; globus pallidus internal segment, GPi; globus pallidus external segment, 
GPe; microtubule associated protein 2, MAP2; nicotinamide adenine dinucleotide phosphate, NADPH; 
PV; parvalbumin.putamen, PUT.  
 
Figure 2. Inflammatory response to cell suspension grafts. Series of double and triple immunostainings 
to visualize the inflammatory response to the grafted cells. A-B. Double immunohistochemical staining 
for Iba1 using nickel-intensified DAB (microglial cells in black) and NeuN as revealed using the 
chromogen DAB (neuronal cell in brown) in selected grafts. B-B’. Representative images of the clear 
gradient in microglial response intensity (C) as well as various microglial morphologies within and 
surrounding the grafts. C-K. Higher power magnification of grafted areas, showing microglial activation 
at the graft-host border (C, E), within P-zones (D), NP-zones (F), clusters of activated cells (G), and host 
cells (H), illustrating the intensity of the microglial response as well as the various phenotypes of the 
activated cells. Pro-inflammatory microglia are identifiable by the increased Iba1 reactivity and 
shortened process length (E). Highly dystrophic microglia in the host were often missing processes 
entirely (H), or otherwise displaying beaded, broken processes (I). Slightly activated microglia (J) and rod 
cells (K) were present within non P-zones. L. Pie charts detailing the percentages of microglial cell 
populations found at different structures or graft interfaces. Scale bars: A, B = 1mm; B’ = 50µm; B” = 
35µm; C, D, E, I = 30µm; F = 80µm; G = 20µm; H, J, K = 15µm. 
 
Figure 3. Graft innervation, presence of HD-related pathology and T-cell response to cell suspension 
grafts. A-B. Tyrosine hydroxylase immunostaining demonstrated modest innervation of the grafts by the 
dopaminergic system of the host. In some grafts (C), as well as at the border of the grafts (D), the 
presence of mHtt was abundant. Within the grafted area, mHtt was observable both within the 
extracellular matrix (E, F) and also within the nucleus of a number of cells within the graft site (F-H, 
chevrons). In addition to being localized within cell bodies of the host (I, I’), mHtt was observable within 
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(J, K) and along dendritic paths of cells within the graft or within cells that had a complex arborisation 
(L). Both CD4 (M, N,) and CD8 staining (O-R) revealed clusters of infiltrating cells within the grafts and 
around blood vessels found within the transplants. On rare occasions, mHtt was seen within CD8+ cells 
(R). Scale bars: A = 175µm; B-C = 100µm; D, I, J, K = 50µm; E, F, I’, L = 25µm; G = 35µm; H = 20µm. M, N, 
O = 60µm; P = 100µm; Q = 30µm; R = 8µm. Abbreviations: CD4, cluster of differentiation 4; cluster of 
differentiation 8, CD8; mutant huntingtin protein, mHtt; TH, tyrosine hydroxylase.  
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